Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism

Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism

US Patent 10369161 · Granted Aug 6, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Procedure for crystallization of (22E)-(24R)-2-methylene-22-dehydro-1α,24-25-tri2023
Procedure for crystallization of (22E)-(24R)-2-methylene-22-dehydro-1α,24-25-tri2023
Procedure for crystallization of (22E)-(24R)-2-methylene-22-dehydro-1α,24-25-tri2023
Use of homosalate and octyl salicylate to treat multiple sclerosis2022
Use of homosalate and octyl salicylate to treat multiple sclerosis2022
Method of treating multiple sclerosis2022
Methods for detecting 1,25-dihydroxyvitamin D and related antibodies2022
Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarke2021
Method for treating multiple sclerosis2020
Methods for detecting 1,25-dihydroxyvitamin D and related antibodies2019
(20S)-1-α,25-dihydroxy-24,24-difluoro-19-nor-vitamin D3 analogs and their pharma2019
(20S)-1-α,25-dihydroxy-24,24-difluoro-19-nor-vitamin D3 analogs and their pharma2019